News Sentiment

CURX sentiment intelligence

Curanex Pharmaceuticals Inc Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.21 Week of 17 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-7.7% over one week, -26.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Cup and Handle

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -7.7% Price reacting lower
Trend fit Trend inactive -26.5% over four weeks
Fair value -76.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 29
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 8
TradingKey 8
Stock Titan 7
dars.gov.et 3
Investing.com Nigeria 2
simplywall.st 2
TIKR.com 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 20
Regulatory and legal 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Investing.com Nigeria Direct company coverage

Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com

This article reports on the filing of Form DEF 14C by Curanex Pharmaceuticals Inc. The document is dated for June 29. The article provides this basic information along with stock performance data for CURX and various market indices.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 22:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Curanex (CURX) OKs 5.7M-share incentive plan and 1:10–1:50 reverse split

Curanex Pharmaceuticals Inc. (CURX) stockholders have approved a 2026 Equity Incentive Plan, reserving up to 5,700,000 shares, and authorized a reverse stock split with a ratio between 1-for-10 and 1-for-50. These actions aim to attract and retain personnel and help regain compli

Tone
Negative 37/100
Event
Market update
Published
29 Jun 2026 14:42
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX

This article provides financial information for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to revenue (forward). The content highlights the company's financials, news, and community discussions available on TradingView. It indicates

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX

This page provides financial data for Curanex Pharmaceuticals Inc (NASDAQ: CURX), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a stub or a placeholder from TradingView, indicating where this financial information would typicall

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX

This article provides financial data for Curanex Pharmaceuticals Inc. It focuses on the company's "Price to book forward" metric, displayed within the TradingView platform. The content confirms that the market was closed at the time of viewing, showing no trades.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 17:41
Source
TradingView
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Curanex Pharmaceuticals Inc (CURX), focusing on its support, resistance, key indicators, and moving averages. The analysis identifies several sell signals across various technical indicators and moving averages, suggesting a bearish o

Tone
Negative 13/100
Event
Market update
Published
22 Jun 2026 07:40
Source
TradingKey
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Curanex Pharmaceuticals Inc (CURX), listing its major individual and institutional investors and their respective proportions. It includes data on shareholder types, institutional holdings over several quarters, and recent changes

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 01:40
Source
TradingKey
TradingView Direct company coverage

Number of shareholders of Curanex Pharmaceuticals Inc – NASDAQ:CURX

This article focuses on the number of shareholders for Curanex Pharmaceuticals Inc, traded on NASDAQ under the symbol CURX. It highlights that the information will be displayed in the "Period Value Change Change %" section. The content primarily provides navigation and structural

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 12:10
Source
TradingView
Stock Titan Direct company coverage

Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M‑share plan and 1:10–1:50 reverse split

Curanex Pharmaceuticals (CURX) has approved a 2026 Equity Incentive Plan, reserving up to 5.7 million shares, and authorized a reverse stock split at a ratio between 1-for-10 and 1-for-50. These corporate actions, approved by majority stockholders via written consent on June 11,

Tone
Negative 33/100
Event
Market update
Published
18 Jun 2026 21:09
Source
Stock Titan
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Institutional Confidence

This article provides an overview of Curanex Pharmaceuticals Inc. (CURX) focusing on its institutional confidence and shareholding data. It lists key shareholders including individuals like Liu (Jun) and Liu (Chang), and institutional investors such as Citadel Advisors LLC and Tw

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 19:09
Source
TradingKey
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Curanex Pharmaceuticals Inc (CURX), highlighting its current stock performance, market capitalization, and a lack of disclosed financial forecasting data for EPS, Revenue, Net Profit, and EBIT. It notes that analyst ratings and targe

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 18:40
Source
TradingKey
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Curanex Pharmaceuticals Inc (CURX), focusing on its P/E, P/B, and P/S ratios. The report indicates that relevant data for these valuation metrics have not yet been disclosed by the company. The stock closed at $0.318, experiencing a 5

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 16:09
Source
TradingKey
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Curanex Pharmaceuticals Inc. (CURX), focusing on its financial health, profitability, and balance sheet. However, the report indicates that relevant financial data for key metrics such as cash and cash equivalents, total assets, revenue, opera

Tone
Negative 42/100
Event
Earnings
Published
18 Jun 2026 16:09
Source
TradingKey
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and stock splits for Curanex Pharmaceuticals Inc (CURX). It indicates that the company has not distributed any dividends over the past five years and there is no data available for stock splits. The information is pr

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 09:39
Source
TradingKey
Finviz Direct company coverage

CURX - Curanex Pharmaceuticals Inc Stock Price and Quote

Curanex Pharmaceuticals Inc (CURX) stock closed at $0.2652, experiencing a slight decrease of 0.30%. The company has a market capitalization of $7.53M and has been actively reporting on business progress and pipeline expansion, particularly for its Phyto-N candidate in cancer cac

Tone
Neutral 50/100
Event
Market update
Published
30 May 2026 22:10
Source
Finviz
Morningstar Direct company coverage

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

Wolf Haldenstein Adler Freeman & Herz LLP has launched an investigation into potential securities fraud claims against Curanex Pharmaceuticals Inc. (NASDAQ: CURX) and its officers/directors. The investigation stems from the company's IPO in August 2025, where shares initially ros

Tone
Negative 29/100
Event
Regulatory and legal
Published
24 May 2026 07:10
Source
Morningstar
Stock Titan Direct company coverage

Colitis drug edges toward FDA review as Curanex targets cancer wasting

Curanex (CURX) reported significant progress in Q1 2026 for its lead candidate Phyto-N, aiming for a Q4 2026 IND submission to the FDA for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable results, and expanded its pipeline t

Tone
Positive 65/100
Event
Earnings
Published
17 May 2026 00:09
Source
Stock Titan
Stock Titan Direct company coverage

CURX Financials: Income Statement, Balance Sheet & Cash Flow

This article provides a detailed financial overview of CURANEX PHARMACEUTICALS INC (CURX) for fiscal year 2025, derived from SEC filings. The company reported a net loss of -$4.2M, with an operating cash outflow of -$10.5M, indicating significant cash burn funded by external fina

Tone
Negative 19/100
Event
Balance sheet
Published
15 May 2026 03:40
Source
Stock Titan
Stock Titan Direct company coverage

Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia

Curanex (CURX) provided a Q1 2026 business update, detailing progress for its lead drug candidate, Phyto-N, towards a Q4 2026 Investigational New Drug (IND) submission for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable res

Tone
Positive 63/100
Event
Regulatory and legal
Published
14 May 2026 13:15
Source
Stock Titan